Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: December 15, 2003
Last updated: July 23, 2015
Last verified: July 2015

An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.

Condition Intervention Phase
Alzheimer's Disease
Drug: MK0677
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Cognitive function over 12 month period; safety and tolerability [ Time Frame: over 12 month period ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog. [ Time Frame: over a 6 month and 12 month period ] [ Designated as safety issue: No ]

Enrollment: 512
Study Start Date: October 2003
Study Completion Date: January 2006
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
  • Patients must have probable Alzheimer's disease of mild or moderate severity.
  • A brain scan and laboratory results must be consistent with Alzheimer's disease.
  • The patient must be otherwise medically healthy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00074529

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00074529     History of Changes
Other Study ID Numbers: 0677-030, Formally-BG0812AZ, MK0677-030, 2006_412
Study First Received: December 15, 2003
Last Updated: July 23, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Tauopathies processed this record on October 08, 2015